We just received data on a new analyst forecast for $CYTK. Gena Wang from Barclays set a price target of 87.0 for CYTK.
To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.
Should you buy $CYTK?
Some analysts are better than others. To view the past performance of Barclays, check out Quiver’s Analyst Ratings dashboard. You can also see Quiver’s Analyst Buys Strategy, which uses a proprietary method to track the companies being recommended by the top Wall Street analysts.
$CYTK Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 14 analysts offer price targets for $CYTK in the last 6 months, with a median target of $85.5.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $87.0 on 01/28/2026
- Mayank Mamtani from B. Riley Securities set a target price of $108.0 on 01/21/2026
- Leonid Timashev from RBC Capital set a target price of $95.0 on 01/21/2026
- Tessa Romero from JP Morgan set a target price of $74.0 on 01/20/2026
- Jeffrey Hung from Morgan Stanley set a target price of $71.0 on 12/23/2025
- Serge Belanger from Needham set a target price of $84.0 on 12/22/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $136.0 on 12/22/2025
$CYTK Insider Trading Activity
$CYTK insiders have traded $CYTK stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 6 sales selling 72,135 shares for an estimated $4,659,920.
- EDWARD M. MD KAYE has made 0 purchases and 5 sales selling 53,447 shares for an estimated $3,321,199.
- WENDELL WIERENGA has made 0 purchases and 2 sales selling 24,375 shares for an estimated $1,579,525.
- ROBERT I BLUM (President & CEO) has made 0 purchases and 6 sales selling 30,000 shares for an estimated $1,574,450.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 10 sales selling 21,000 shares for an estimated $1,152,256.
- JOHN T HENDERSON sold 8,750 shares for an estimated $559,125
- B LYNNE PARSHALL sold 5,000 shares for an estimated $323,650
- ROBERT ARTHUR HARRINGTON has made 0 purchases and 2 sales selling 4,300 shares for an estimated $248,260.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CYTK Congressional Stock Trading
Members of Congress have traded $CYTK stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 10/09.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$CYTK Hedge Fund Activity
We have seen 223 institutional investors add shares of $CYTK stock to their portfolio, and 132 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP removed 2,250,000 shares (-75.6%) from their portfolio in Q3 2025, for an estimated $123,660,000
- FMR LLC added 1,824,136 shares (+16.2%) to their portfolio in Q3 2025, for an estimated $100,254,514
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,478,056 shares (+8.4%) to their portfolio in Q3 2025, for an estimated $81,233,957
- WOODLINE PARTNERS LP added 1,435,422 shares (+676.1%) to their portfolio in Q3 2025, for an estimated $78,890,793
- UBS GROUP AG removed 1,267,414 shares (-41.3%) from their portfolio in Q3 2025, for an estimated $69,657,073
- ALLIANCEBERNSTEIN L.P. removed 1,150,537 shares (-83.0%) from their portfolio in Q3 2025, for an estimated $63,233,513
- ORBIMED ADVISORS LLC removed 1,077,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $59,191,920
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
